Tildrakizumab induction therapy followed by as needed dosing in patients with mild-to-moderate psoriasis. de Aragon CA, Berna-Rico E, Goas A, Perez-Bootello J, et al. Clin Exp Dermatol 2023 Oct 25:llad361. doi: 10.1093.

Read + Share

Amedeo Smart

Independent Medical Education

de Aragon CA, Berna-Rico E, Goas A, Perez-Bootello J, et al. Tildrakizumab induction therapy followed by as needed dosing in patients with mild-to-moderate psoriasis. Clin Exp Dermatol 2023 Oct 25:llad361. doi: 10.1093.
PMID: 37878574